Page 77 - Genentech News Today

PagerDuty, Inc. , a leader in digital operations management, today announced it will release its financial results for the third quarter fiscal year 2024, ended October 31, 2023, after market close...

Tokyo, Japan and Cambridge, UK, 10 November 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the third quarter and nine months ended 30 September 2023. The full report can be found by clicking here. Chris Cargill, President & CEO of Sosei Heptares, commented: “The third quarter has been an exciting and transformational period for the Gr...

Chinese medicine offers an alternative viewpoint of treating breast cancer based on opening up meridians in the body that allow Qi energy to flow unimpeded.

(BPT) - Roy Bragadeste, a husband and father, was living in Seattle and enjoying what many would describe as a relatively normal life, working, spending time with his wife, kids and dog, and enjoying …

Enrollment Continues in Phase 2a Clinical Study of RG6501 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration Under Management of Genentech, a Member of the Roche...

SYDNEY, Nov. 10, 2023 /PRNewswire/ -- Kazia Therapeutics Limited , an oncology-focused drug development company, is pleased to announce the publication in Molecular Cancer Therapeutics highlighting...

Operator: Thank you for standing by. At this time, I would like to welcome everyone to today’s Adaptive Biotechnologies 2023 Third Quarter Earnings Call.

Secondary trial analysis boosts case for Gazyva

Nicole Lamanna, MD, discusses treatment options for patients with chronic lymphocytic leukemia who develop resistance to a prior treatment.

Entered into a collaboration with Tempus giving Recursion access to over 20 petabytes of multimodal oncology data for the purpose of training causal AI...